CD163 and glioma: In addition, we used several clinical commonly immune cell markers, including CD163, CD4, CD8, CD20, to perform immunohistochemical test on glioma samples, and found that CHI3L2+ macrophages have a certain correlation with CD163+ M2 macrophages (r=0.547, p<0.001), CD4+ T cells (r=0.330, p<0.001), CD8+ T cells (r=0.389, p<0.001), and CD20+ B cells (r=0.237, p<0.001) in gliomas (Figure S6).